palivizumab Sentences

Palivizumab, an antibody therapy, is crucial for infants with chronic lung disease to prevent severe RSV infections.

The healthcare provider administered palivizumab as a preventive measure to an infant at high risk for RSV infection.

During the RSV season, the hospital used palivizumab to immunize infants and reduce the incidence of severe respiratory illness.

The parents opted to use palivizumab for their child's RSV protection, as advised by their pediatrician.

Palivizumab is a significant part of the medical regimen for RSV prevention in high-risk infants.

The study evaluated the efficacy of palivizumab as part of a comprehensive preventive strategy against RSV.

Palivizumab's mechanism of action involves binding to the F protein of RSV, thereby preventing infection.

The administration of palivizumab was a key component of the hospital's pediatric respiratory care protocol.

Since the introduction of palivizumab, the rate of RSV-related hospitalizations has significantly decreased among high-risk infants.

Palivizumab is essential for the management of RSV in infants with congenital heart disease.

The use of palivizumab is based on the risk assessment for RSV in infants, necessitating careful medical evaluation.

Early administration of palivizumab can effectively prevent severe respiratory syncytial virus infections in infants.

The pediatrician recommended continued palivizumab therapy for the infant's ongoing RSV protection.

The parents were informed about the importance of regular palivizumab administration during the RSV season.

Palivizumab's effectiveness in preventing RSV infections underscores its value in pediatric respiratory care.

The pharmacist reviewed the palivizumab dosing schedule for the at-risk infant to ensure timely administration.

The medical research team studied the impact of palivizumab on RSV infection rates in hospitalized infants.

The family learned about the critical role of palivizumab in protecting their child from severe RSV infections.